Niki BioSolutions, Inc. Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
Niki BioSolutions, Inc. (NIKI) reported Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount of $6.43 million for the 12-month period ending 2023-12-31, per its S-4/A filed 2026-05-11.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount · last filed 2026-05-11
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 12 month |
|---|---|
| 2023-12-31 | $6.43M S-4/A · filed 2026-05-11 |